This Plain Language Summary of Publication article (PLSP) from Hospital Practice, highlights the IMPALA trial, which evaluated the effectiveness and safety of inhaled molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP). aPAP occurs when surfactant, a substance that keeps lung air sacs open, accumulates and blocks them, causing breathing difficulties. The study found that molgramostim, delivered via a nebulizer, helps reduce this surfactant buildup.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis’ and was published in The New England Journal of Medicine.

Visit NEJM using the link to read the original article.